At the insistence of Justice Neil Gorsuch, she withdrew the allegation that the other side had lied but held firm to the ...

Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

Novavax is working with the FDA to meet additional requirements and hopes to secure full approval as soon as possible.

Shares of Novavax (NVAX) are under pressure on Thursday ... composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” ...

When asked if the delay resulted from "personnel being shuffled" at the FDA, Kennedy attributed it to the vaccine's composition. He said Novavax's single antigen approach "has never worked" for ...

The FDA gave full approval to COVID-19 shots from ... PRICE ACTION: In Thursday morning trading, shares of Novavax have dropped over 24% to $5.13. Published first on TheFly – the ultimate ...

Beyond the pending Novavax approval, the FDA must in the coming weeks advise Covid vaccine manufacturers on how to update their shots for the 2025-2026 respiratory season. The agency is also ...

Novavax intends to seek a business partner to ... And Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, who was instrumental in the development and ...

the US Food and Drug Administration delayed a decision on full approval of Novavax’s Covid-19 vaccine even though it was on track to be cleared, leaving many public health experts wondering why. A ...

Already, the FDA has missed its deadline for deciding on approval of Novavax’s COVID-19 shot. Novavax expected to hear back from the FDA about a full, traditional approval for its protein-based ...

The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. HealthDay News — The US Food and Drug Administration (FDA) has delayed the full ...